Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Updated Oct 4, 2026
AI dilution summary: the dominant contractual driver and its mechanism, then each further driver ranked, for Signal8 Pro subscribers.
